Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions

Sung Hoon Jung; Youngil Koh; Min Kyoung Kim; Jin Seok Kim; Joon Ho Moon; Chang Ki Min; Dok Hyun Yoon; Sung Soo Yoon; Je Jung Lee; Chae Moon Hong; Ka Won Kang; Jihyun Kwon; Kyoung Ha Kim; Dae Sik Kim; Sung Yong Kim; Sung Hyun Kim; Yu Ri Kim; Young Rok Do; Yeung Chul Mun; Sung Soo Park; Young Hoon Park; Ho Jin Shin; Hyeon Seok Eom; Sang Eun Yoon; Sang Mee Hwang; Won Sik Lee; Myung Won Lee; Jun Ho Yi; Ji Yun Lee; Ji Hyun Lee; Ho Sup Lee; Sung Nam Lim; Jihyang Lim; Ho Young Yhim; Yoon Hwan Chang; Jae Cheol Jo; Jinhyun Cho; Hyungwoo Cho; Yoon Seok Choi; Hee jeong Cho; Ari Ahn; Jong Han Choi; Hyun Jung Kim; Kihyun Kim

doi:10.1007/s44313-025-00055-9

Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions

Sung Hoon Jung, Youngil Koh, Min Kyoung Kim, Jin Seok Kim, Joon Ho Moon, Chang Ki Min, Dok Hyun Yoon, Sung Soo Yoon, Je Jung Lee, Chae Moon Hong, Ka Won Kang, Jihyun Kwon, Kyoung Ha Kim, Dae Sik Kim, Sung Yong Kim, Sung Hyun Kim, Yu Ri Kim, Young Rok Do, Yeung Chul Mun, Sung Soo ParkYoung Hoon Park, Ho Jin Shin, Hyeon Seok Eom, Sang Eun Yoon, Sang Mee Hwang, Won Sik Lee, Myung Won Lee, Jun Ho Yi, Ji Yun Lee, Ji Hyun Lee, Ho Sup Lee, Sung Nam Lim, Jihyang Lim, Ho Young Yhim, Yoon Hwan Chang, Jae Cheol Jo, Jinhyun Cho, Hyungwoo Cho, Yoon Seok Choi, Hee jeong Cho, Ari Ahn, Jong Han Choi, Hyun Jung Kim, Kihyun Kim

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Multiple myeloma (MM), a hematological malignancy, is characterized by malignant plasma cell proliferation in the bone marrow. Recent treatment advances have significantly improved patient outcomes associated with MM. In this study, we aimed to develop comprehensive, evidence-based guidelines for the diagnosis, prognosis, and treatment of MM. We identified 12 key clinical questions essential for MM management, guiding the extensive literature review and meta-analysis of the study. Our guidelines provide evidence-based recommendations by integrating patient preferences with survey data. These recommendations include current and emerging diagnostic tools, therapeutic agents, and treatment strategies. By prioritizing a patient-centered approach and rigorous data analysis, these guidelines were developed to enhance MM management, both in Korea and globally.

Original language	English
Article number	9
Journal	Blood Research
Volume	60
Issue number	1
DOIs	https://doi.org/10.1007/s44313-025-00055-9
State	Published - Dec 2025

Bibliographical note

Publisher Copyright:
© The Author(s) 2025.

Keywords

Guidelines
Meta-analysis
Multiple myeloma
Prognosis
Treatment

Access to Document

10.1007/s44313-025-00055-9

Cite this

Jung, S. H., Koh, Y., Kim, M. K., Kim, J. S., Moon, J. H., Min, C. K., Yoon, D. H., Yoon, S. S., Lee, J. J., Hong, C. M., Kang, K. W., Kwon, J., Kim, K. H., Kim, D. S., Kim, S. Y., Kim, S. H., Kim, Y. R., Do, Y. R., Mun, Y. C., ... Kim, K. (2025). Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions. Blood Research, 60(1), Article 9. https://doi.org/10.1007/s44313-025-00055-9

@article{669a1f5adbd84bbfa20e32103c047b12,

title = "Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions",

abstract = "Multiple myeloma (MM), a hematological malignancy, is characterized by malignant plasma cell proliferation in the bone marrow. Recent treatment advances have significantly improved patient outcomes associated with MM. In this study, we aimed to develop comprehensive, evidence-based guidelines for the diagnosis, prognosis, and treatment of MM. We identified 12 key clinical questions essential for MM management, guiding the extensive literature review and meta-analysis of the study. Our guidelines provide evidence-based recommendations by integrating patient preferences with survey data. These recommendations include current and emerging diagnostic tools, therapeutic agents, and treatment strategies. By prioritizing a patient-centered approach and rigorous data analysis, these guidelines were developed to enhance MM management, both in Korea and globally.",

keywords = "Guidelines, Meta-analysis, Multiple myeloma, Prognosis, Treatment",

author = "Jung, \{Sung Hoon\} and Youngil Koh and Kim, \{Min Kyoung\} and Kim, \{Jin Seok\} and Moon, \{Joon Ho\} and Min, \{Chang Ki\} and Yoon, \{Dok Hyun\} and Yoon, \{Sung Soo\} and Lee, \{Je Jung\} and Hong, \{Chae Moon\} and Kang, \{Ka Won\} and Jihyun Kwon and Kim, \{Kyoung Ha\} and Kim, \{Dae Sik\} and Kim, \{Sung Yong\} and Kim, \{Sung Hyun\} and Kim, \{Yu Ri\} and Do, \{Young Rok\} and Mun, \{Yeung Chul\} and Park, \{Sung Soo\} and Park, \{Young Hoon\} and Shin, \{Ho Jin\} and Eom, \{Hyeon Seok\} and Yoon, \{Sang Eun\} and Hwang, \{Sang Mee\} and Lee, \{Won Sik\} and Lee, \{Myung Won\} and Yi, \{Jun Ho\} and Lee, \{Ji Yun\} and Lee, \{Ji Hyun\} and Lee, \{Ho Sup\} and Lim, \{Sung Nam\} and Jihyang Lim and Yhim, \{Ho Young\} and Chang, \{Yoon Hwan\} and Jo, \{Jae Cheol\} and Jinhyun Cho and Hyungwoo Cho and Choi, \{Yoon Seok\} and Cho, \{Hee jeong\} and Ari Ahn and Choi, \{Jong Han\} and Kim, \{Hyun Jung\} and Kihyun Kim",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = dec,

doi = "10.1007/s44313-025-00055-9",

language = "English",

volume = "60",

journal = "Blood Research",

issn = "2287-979X",

publisher = "Springer",

number = "1",

}

Jung, SH, Koh, Y, Kim, MK, Kim, JS, Moon, JH, Min, CK, Yoon, DH, Yoon, SS, Lee, JJ, Hong, CM, Kang, KW, Kwon, J, Kim, KH, Kim, DS, Kim, SY, Kim, SH, Kim, YR, Do, YR, Mun, YC, Park, SS, Park, YH, Shin, HJ, Eom, HS, Yoon, SE, Hwang, SM, Lee, WS, Lee, MW, Yi, JH, Lee, JY, Lee, JH, Lee, HS, Lim, SN, Lim, J, Yhim, HY, Chang, YH, Jo, JC, Cho, J, Cho, H, Choi, YS, Cho, HJ, Ahn, A, Choi, JH, Kim, HJ & Kim, K 2025, 'Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions', Blood Research, vol. 60, no. 1, 9. https://doi.org/10.1007/s44313-025-00055-9

TY - JOUR

T1 - Evidence-based Korean guidelines for the clinical management of multiple myeloma

T2 - addressing 12 key clinical questions

AU - Jung, Sung Hoon

AU - Koh, Youngil

AU - Kim, Min Kyoung

AU - Kim, Jin Seok

AU - Moon, Joon Ho

AU - Min, Chang Ki

AU - Yoon, Dok Hyun

AU - Yoon, Sung Soo

AU - Lee, Je Jung

AU - Hong, Chae Moon

AU - Kang, Ka Won

AU - Kwon, Jihyun

AU - Kim, Kyoung Ha

AU - Kim, Dae Sik

AU - Kim, Sung Yong

AU - Kim, Sung Hyun

AU - Kim, Yu Ri

AU - Do, Young Rok

AU - Mun, Yeung Chul

AU - Park, Sung Soo

AU - Park, Young Hoon

AU - Shin, Ho Jin

AU - Eom, Hyeon Seok

AU - Yoon, Sang Eun

AU - Hwang, Sang Mee

AU - Lee, Won Sik

AU - Lee, Myung Won

AU - Yi, Jun Ho

AU - Lee, Ji Yun

AU - Lee, Ji Hyun

AU - Lee, Ho Sup

AU - Lim, Sung Nam

AU - Lim, Jihyang

AU - Yhim, Ho Young

AU - Chang, Yoon Hwan

AU - Jo, Jae Cheol

AU - Cho, Jinhyun

AU - Cho, Hyungwoo

AU - Choi, Yoon Seok

AU - Cho, Hee jeong

AU - Ahn, Ari

AU - Choi, Jong Han

AU - Kim, Hyun Jung

AU - Kim, Kihyun

PY - 2025/12

Y1 - 2025/12

N2 - Multiple myeloma (MM), a hematological malignancy, is characterized by malignant plasma cell proliferation in the bone marrow. Recent treatment advances have significantly improved patient outcomes associated with MM. In this study, we aimed to develop comprehensive, evidence-based guidelines for the diagnosis, prognosis, and treatment of MM. We identified 12 key clinical questions essential for MM management, guiding the extensive literature review and meta-analysis of the study. Our guidelines provide evidence-based recommendations by integrating patient preferences with survey data. These recommendations include current and emerging diagnostic tools, therapeutic agents, and treatment strategies. By prioritizing a patient-centered approach and rigorous data analysis, these guidelines were developed to enhance MM management, both in Korea and globally.

AB - Multiple myeloma (MM), a hematological malignancy, is characterized by malignant plasma cell proliferation in the bone marrow. Recent treatment advances have significantly improved patient outcomes associated with MM. In this study, we aimed to develop comprehensive, evidence-based guidelines for the diagnosis, prognosis, and treatment of MM. We identified 12 key clinical questions essential for MM management, guiding the extensive literature review and meta-analysis of the study. Our guidelines provide evidence-based recommendations by integrating patient preferences with survey data. These recommendations include current and emerging diagnostic tools, therapeutic agents, and treatment strategies. By prioritizing a patient-centered approach and rigorous data analysis, these guidelines were developed to enhance MM management, both in Korea and globally.

KW - Guidelines

KW - Meta-analysis

KW - Multiple myeloma

KW - Prognosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85218474370&partnerID=8YFLogxK

U2 - 10.1007/s44313-025-00055-9

DO - 10.1007/s44313-025-00055-9

M3 - Review article

AN - SCOPUS:85218474370

SN - 2287-979X

VL - 60

JO - Blood Research

JF - Blood Research

IS - 1

M1 - 9

ER -

Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this